Table 4 Incidence of adverse events >5% in any treatment group in any study
|  | DURATION-4* | DURATION-2†| DURATION-3‡ | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | ExQW | Met | Sita | Pio | ExQW | Sita | Pio | ExQW | IG |
| Â | (N = 248) | (N = 246) | (N = 163) | (N = 163) | (N = 160) | (N = 166) | (N = 165) | (N = 233) | (N = 223) |
Arthralgia (%) | 5 | 1 | 2 | 3 | 3 | 5 | 2 | 4 | 3 |
Back pain (%) | 2 | 6 | 3 | 4 | 4 | 4 | 3 | 4 | 2 |
Constipation (%) | 9 | 3 | 3 | 2 | 6 | 2 | 1 | 3 | 2 |
Diarrhea (%) | 11 | 13 | 6 | 4 | 18 | 10 | 7 | 9 | 4 |
Dyspepsia (%) | 7 | 3 | 2 | 5 | 4 | 4 | 2 | 3 | 1 |
Fatigue (%) | 1 | 0 | 1 | 1 | 6 | 0 | 3 | 3 | <1 |
Headache (%) | 8 | 12 | 9 | 8 | 9 | 9 | 4 | 10 | 7 |
Hypertension (%) | 1 | 1 | 2 | 7 | 3 | 3 | 1 | 2 | 3 |
Injection site nodule (%) | 11 | 10 | 7 | 4 | 3 | 1 | 1 | 6 | 0 |
Injection site pruritus (%) | 4 | 2 | 1 | 1 | 5 | 5 | 1 | 1 | <1 |
Nasopharyngitis (%) | 8 | 5 | 10 | 9 | 4 | 2 | 3 | 13 | 18 |
Nausea (%) | 11 | 7 | 4 | 4 | 24 | 10 | 5 | 13 | 1 |
Peripheral edema (%) | 0 | <1 | 1 | 7 | 1 | 3 | 8 | 0 | 0 |
Sinusitis (%) | <1 | <1 | 0 | 2 | 3 | 1 | 7 | 1 | 2 |
Urinary tract infection (%) | 1 | 2 | 1 | 1 | 6 | 5 | 4 | 1 | <1 |
Upper-respiratory tract infection (%) | 3 | 3 | 1 | 2 | 4 | 9 | 10 | 2 | 1 |
Vomiting (%) | 5 | 3 | 2 | 3 | 11 | 2 | 3 | 4 | 1 |